Patents by Inventor Wei BU

Wei BU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12005115
    Abstract: Vaccines are provided that elicit neutralizing antibodies to Epstein-Barr virus (EBV). Some vaccines comprise nanoparticles that display envelope proteins from EBV on their surface. The nanoparticles comprise fusion proteins comprising a monomeric subunit of a self-assembly protein, such as ferritin, joined to at least a portion of an EBV envelope protein. The fusion proteins self-assemble to form the envelope protein-displaying nanoparticles. Such vaccines can be used to vaccinate an individual against infection by different types of Epstein-Barr viruses as well as Epstein-Barr viruses that are antigenically divergent from the virus from which the EBV envelope protein was obtained. Also provided are fusion proteins and nucleic acid molecules encoding such proteins.
    Type: Grant
    Filed: July 7, 2020
    Date of Patent: June 11, 2024
    Assignee: The United States of America as Represented By The Secretary of the Department of Health and Human Services
    Inventors: Masaru Kanekiyo, Gary J. Nabel, Jeffrey Cohen, Wei Bu
  • Publication number: 20240174735
    Abstract: Antibodies and compositions of matter useful for the detection, diagnosis and treatment of Epstein Barr Virus (EBV) infection in mammals, and methods of using those compositions of matter for the detection, diagnosis and treatment of EBV infection are described. Also described are proteins, referred to as anti-gp350 antibody probes, and anti-gp350 B-cell probes, that maintain the epitope structure of the CR2-binding region of gp350, but do not bind CR2.
    Type: Application
    Filed: February 13, 2024
    Publication date: May 30, 2024
    Applicants: The U.S.A., as represented by the Secretary, Department of Health and Human Services, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Wei Bu, Masaru Kanekiyo, Michael Gordon Joyce, Jeffrey I. Cohen
  • Patent number: 11926656
    Abstract: Antibodies and compositions of matter useful for the detection, diagnosis and treatment of Epstein Barr Virus (EBV) infection in mammals, and methods of using those compositions of matter for the detection, diagnosis and treatment of EBV infection are described. Also described are proteins, referred to as anti-gp350 antibody probes, and anti-gp350 B-cell probes, that maintain the epitope structure of the CR2-binding region of gp350, but do not bind CR2.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: March 12, 2024
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Wei Bu, Masaru Kanekiyo, Michael Gordon Joyce, Jeffrey I. Cohen
  • Publication number: 20230348568
    Abstract: Monoclonal antibodies that specifically bind gp42 of Epstein-Barr virus (EBV) are described. The antibodies are capable of blocking fusion of EBV-infected cells and neutralizing EBV infection. Use of the EBV-specific monoclonal antibodies, and conjugates thereof, for the treatment and prophylaxis of EBV infection is also described.
    Type: Application
    Filed: February 19, 2021
    Publication date: November 2, 2023
    Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventors: Jeffrey I. Cohen, Wei Bu, Nathan Board, Kennichi Dowdell
  • Publication number: 20220098284
    Abstract: Antibodies and compositions of matter useful for the detection, diagnosis and treatment of Epstein Barr Virus infection in mammals, and methods of using those compositions of matter for the same are disclosed. Also disclosed are proteins, referred to as anti-gp350 antibody probes, and anti-gp350 B-cell probes, that maintain the epitope structure of the CR2-binding region of gp350, but do not bind CR2.
    Type: Application
    Filed: December 16, 2021
    Publication date: March 31, 2022
    Applicants: The U.S.A., as represented by the Secretary, Department of Health and Human Services, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Wei Bu, Masaru Kanekiyo, Michael Gordon Joyce, Jeffrey I. Cohen
  • Patent number: 11236151
    Abstract: Antibodies and compositions of matter useful for the detection, diagnosis and treatment of Epstein Barr Virus infection in mammals, and to methods of using those compositions of matter for the same. Also disclosed are proteins, referred to as anti-gp350 antibody probes, and anti-gp350 B-cell probes, that maintain the epitope structure of the CR2-binding region of gp350, but do not bind CR2.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: February 1, 2022
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Wei Bu, Masaru Kanekiyo, Michael Gordon Joyce, Jeffrey I. Cohen
  • Publication number: 20210171610
    Abstract: Anti-EBV gH antibodies, anti-EBV gL antibodies, anti-EBV gH/gL antibodies, and compositions of matter useful for the detection, diagnosis, prevention, and treatment of Epstein Barr Virus infection in humans, and methods of using those compositions of matter for the same.
    Type: Application
    Filed: May 2, 2019
    Publication date: June 10, 2021
    Applicants: The U.S.A., as represented by the Secretary, Department of Health and Human Services, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Masaru Kanekiyo, Michael Gordon Joyce, Wei Bu, Jeffrey I. Cohen, Yaroslav Tsybovsky
  • Publication number: 20200330587
    Abstract: Vaccines are provided that elicit neutralizing antibodies to Epstein-Barr virus (EBV). Some vaccines comprise nanoparticles that display envelope proteins from EBV on their surface. The nanoparticles comprise fusion proteins comprising a monomeric subunit of a self-assembly protein, such as ferritin, joined to at least a portion of an EBV envelope protein. The fusion proteins self-assemble to form the envelope protein-displaying nanoparticles. Such vaccines can be used to vaccinate an individual against infection by different types of Epstein-Barr viruses as well as Epstein-Barr viruses that are antigenically divergent from the virus from which the EBV envelope protein was obtained. Also provided are fusion proteins and nucleic acid molecules encoding such proteins.
    Type: Application
    Filed: July 7, 2020
    Publication date: October 22, 2020
    Inventors: Masaru Kanekiyo, Gary J. Nabel, Jeffrey Cohen, Wei Bu
  • Patent number: 10744199
    Abstract: Vaccines are provided that elicit neutralizing antibodies to Epstein-Barr virus (EBV). Some vaccines comprise nanoparticles that display envelope proteins from EBV on their surface. The nanoparticles comprise fusion proteins comprising a monomeric subunit of a self-assembly protein, such as ferritin, joined to at least a portion of an EBV envelope protein. The fusion proteins self-assemble to form the envelope protein-displaying nanoparticles. Such vaccines can be used to vaccinate an individual against infection by different types of Epstein-Barr viruses as well as Epstein-Barr viruses that are antigenically divergent from the virus from which the EBV envelope protein was obtained. Also provided are fusion proteins and nucleic acid molecules encoding such proteins.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: August 18, 2020
    Assignee: The USA, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Masaru Kanekiyo, Gary J. Nabel, Jeffrey Cohen, Wei Bu
  • Publication number: 20200190168
    Abstract: Antibodies and compositions of matter useful for the detection, diagnosis and treatment of Epstein Barr Virus infection in mammals, and to methods of using those compositions of matter for the same. Also disclosed are proteins, referred to as anti-gp350 antibody probes, and anti-gp350 B-cell probes, that maintain the epitope structure of the CR2-binding region of gp350, but do not bind CR2.
    Type: Application
    Filed: April 25, 2018
    Publication date: June 18, 2020
    Inventors: Wei BU, Masaru KANEKIYO, Michael Gordon JOYCE, Jeffrey I. COHEN
  • Publication number: 20160303224
    Abstract: Vaccines are provided that elicit neutralizing antibodies to Epstein-Barr virus (EBV). Some vaccines comprise nanoparticles that display envelope proteins from EBV on their surface. The nanoparticles comprise fusion proteins comprising a monomeric subunit of a self-assembly protein, such as ferritin, joined to at least a portion of an EBV envelope protein. The fusion proteins self-assemble to form the envelope protein-displaying nanoparticles. Such vaccines can be used to vaccinate an individual against infection by different types of Epstein-Barr viruses as well as Epstein-Barr viruses that are antigenically divergent from the virus from which the EBV envelope protein was obtained. Also provided are fusion proteins and nucleic acid molecules encoding such proteins.
    Type: Application
    Filed: October 10, 2014
    Publication date: October 20, 2016
    Inventors: Masaru KANEKIYO, Gary J. NABEL, Jeffrey COHEN, Wei BU